Beam Therapeutics disclosed updated safety and efficacy data from its Phase 1/2 study of BEAM‑302, a liver‑targeting base‑editing therapy for alpha‑1 antitrypsin deficiency (AATD). The 60‑mg dose produced a mean steady‑state total AAT level of 16.1 µM, keeping all 29 patients above the 11 µM protective threshold for at least 12 months. The data also showed an 84 % reduction in mutant Z‑AAT and a 94 % composition of corrected M‑AAT in total AAT, with no serious adverse events reported; only mild to moderate infusion‑related reactions and transient liver enzyme elevations were observed.
The sustained AAT levels above the protective threshold and the substantial reduction in toxic Z‑AAT demonstrate that the 60‑mg dose delivers durable biochemical benefit while maintaining a favorable safety profile. Beam’s decision to adopt this dose as the optimal biological dose is based on the balance of efficacy and tolerability observed in the cohort, positioning the therapy for a streamlined regulatory pathway.
The data support Beam’s plan to launch a global pivotal cohort in the second half of 2026 and to pursue accelerated approval based on biomarker endpoints. The results validate the company’s base‑editing platform and reinforce its leadership in liver‑targeting gene therapies. By addressing the underlying genetic defect, BEAM‑302 offers a one‑time curative option for a disease that currently relies on augmentation therapy, potentially transforming the treatment landscape for AATD.
Beam’s updated data reinforce the company’s strategic trajectory and strengthen confidence in its regulatory strategy, underscored by Orphan Drug and RMAT designations. The milestone also highlights the broader potential of base editing for complex genetic disorders, positioning Beam as a key player in the evolving gene‑therapy market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.